Obstetrics & Gynaecology Forum Volume 29 | Issue 3 | 2019

S4 Mirena® Levonorgestrel intrauterine system. Each sterile intrauterine system contains levonorgestrel 52 mg, 20 g/24hrs. Indication: Contraception. Idiopathic Menorrhagia. Protection from endometrial hyperplasia during estrogen replacement therapy. RSA Reg No: 32/34/0332. Namibia: NS1 Mirena® Reg No: 04/34/1017. Botswana: S2 Mirena® Reg No: BOT0700957. For full prescribing information, refer to the package insert approved by the medicines regulatory authority. Bayer (Pty) Ltd Reg. No. 1968/011192/07 27 Wrench Road Isando 1609 South Africa Tel: 011 921 5000. PP-MIR-BW-0006-1 www.bayer.co.za References: * Mirena® South African Package Insert, 2009 1. NICE: Heavy menstrual bleeding: assessment and management. NICE clinical guidelines [CG44]. 2007. Last updated: August 2016. Accessed at nice.org.uk/guidance/cg44 2. American College of Obstetricians and Gynecologists. Management of abnormal uterine bleeding associated with ovulatory dysfunction. Obstet Gynecol 2013;122(1):176–185 3. Faculty of Sexual and Reproductive Healthcare Clinical Guidance. Intrauterine contraception, 2015. Available at: http://www.fsrh . org/standards-and-guidance/documents/ceuguidanceintrauterinecontraception. [Accessed 14 Sep 2017] 4. FEBRASCO, Guia Prático de Condutas – Tratamento do Sangramento Uterino Anormal (Menorragia). Brazil. 2014. 5. Marret, H et al. Clinical practice guidelines on menorrhagia: management of abnormal uterine bleeding before menopause. CNGOF (France). Eur J Obstet Gynecol. 2010;152:133-137 6. Canadian SOGC. Guidelines on Abnormal Uterine Bleeding in Pre-Menopausal Women. J Obstet Gynaecol Can 2013;35(5):473-475 7. Reid PC, et al. Randomised comparative trial of the levonorgestrel intrauterine system and mefenamic acid for the treatment of idiopathic menorrhagia: a multiple analysis using total menstrual fluid loss, menstrual blood loss and pictorial blood loss assessment charts. BJOG 2005;112:1121–1125. 8. Xu, L; Lee, BS; et al. Satisfaction and health-related quality of life in women with heavy menstrual bleeding; results from a non-interventional trial of the levonorgestrel-releasing intrauterine system or conventional medical therapy. International Journal of Women’s Health. 2014; 6 547-554 HEAVY MENSTRUAL BLEEDING (HMB) IS A MEDICAL CONDITION THAT CAN BE TREATED – MIRENA® 1 ST LINE FOR TREATMENTOF HMB 1-6 ONLY I SHOULD BE IN CONTROL– NOT MY PERIOD 95 % 84 % blood loss reduction at 6 months 7 of HMB patients satisfied 8 MIRENA ® OFFERS *